Views & Analysis A novel UK approach to cancer access: yes, no, or maybe? Experts discuss the implications of the new, reinvigorated Cancer Drugs Fund, for pharma and patients.
Views & Analysis ‘Real world’ COPD trial gives GSK a dose of reality Salford Lung Study is a bold experiment, but hasn't fully paid off for GSK.
Views & Analysis Access to cancer drugs: planning for every outcome New UK oncology drug assessment procedures examined.
Articles Does real world evidence matter in Health Technology Assessm... Health Technology Assessment (HTA) agencies usually rely on randomised controlled trials for clinical data when evaluating drugs, but these do not always tell the entire story.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.